CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
抗 PD-1/PD-L1 抗体在复发难治性弥漫大 B 细胞淋巴瘤患者中的疗效和安全性：一项 meta 分析
英文原题：Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis.
查看英文原题
Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本文通过meta分析评估PD-1/PD-L1抑制剂在复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）患者中的安全性和疗效。共初步检索到63篇论文，纳入8项临床研究。ORR的估计效应为[OR = 0.40，95% CI 0.29-0.51；p = 0.08]，完全缓解率的估计效应为[OR = 0.21，95% CI 0.14-0.31；p < 0.001]，而1年无进展生存期的估计效应为[OR = 0.33，95% CI 0.22-0.47；p = 0.01]。1年OS的估计效应为[OR = 0.67，95% CI 0.55-0.77；p = 0.05]。
此外，3级不良事件的估计效应为[OR = 0.33，95% CI 0.22-0.46；p = 0.01]。总体而言，PD-1/PD-L1抑制剂在所选R/R DLBCL试验中显示出欠佳的治疗疗效。
然而，将PD-1/PD-L1抑制剂与CAR-T 联合显示出改善治疗结局的潜力。此外，研究发现PD-1/PD-L1抑制剂在R/R DLBCL患者中是安全的且耐受性良好。
展开英文摘要原文
This article conducts a meta-analysis to evaluate the safety and efficacy of PD-1/PD-L1 inhibitors in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). A total of 63 papers were initially retrieved, and eight clinical studies were collected. The estimated effect of ORR was [OR = 0. 40, 95% CI 0.
29-0. 51; p = 0. 08], the estimated effect of complete response rate was [OR = 0. 21, 95% CI 0. 14-0. 31; p < 0. 001], while the estimated effect of 1-year progression-free survival was [OR = 0. 33, 95% CI 0. 22-0. 47; p = 0. 01]. The estimated effect of 1-year OS was [OR = 0. 67, 95% CI 0. 55-0. 77; p = 0. 05].
In addition, the estimated effect of grade 3 adverse events was [OR = 0. 33, 95% CI 0. 22-0. 46; p = 0. 01].
Overall, PD-1/PD-L1 inhibitors demonstrated suboptimal therapeutic efficacy in the selected trials for R/R DLBCL.
However, combining PD-1/PD-L1 inhibitors with CAR-T showed potential for improved treatment outcomes.
Additionally, PD-1/PD-L1 inhibitors were found to be safe and well-tolerated in patients with R/R DLBCL.
论文信息
- 作者
- Zhang J、Xu L、Sun C、Huang Z、Ma J、Wang L
- 第一作者单位
- Clinical Medicine School, Shandong Second Medical University, No. 4948, Victory East Street, Weifang, Shandong, 261000, China.China
- 通讯作者单位
- Department of Hematology, Shengli Oilfield Central Hospital, No. 31, Jinan Road, Dongying District, Dongying, Shandong, 257034, China.China
- 期刊
- Open life sciences2025
- 原文标识
- PubMed 40771412 · DOI 10.1515/biol-2025-1129
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →